OOIR: Observatory of International Research

Papers

(The H4-Index of Gynecologic Oncology is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Targeting master regulators with general transcription inhibitors in clear cell ovarian cancer	101
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery	96
Patient-reported post-discharge opioid use after abdominal gynecologic surgery in an Enhanced Recovery After Surgery (ERAS) program (004)	94
Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011)	88
Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes	79
Redefining readmissions in gynecologic cancer: readmissions resulting in hospital-to-hospice transitions may represent high value care	78
Stage IV gynecologic cancers patients who subsequently died from disease: lessons learned from their health care journey	74
Sentinel lymph node procedures in endometrial cancer: an international multicenter experience	74
The impact of the SARS-COV2 pandemic on the delivery of chemotherapy for gynecologic cancer at a tertiary care institution in the United States epicenter	70
Taking the ‘first steps’ to a healthier lifestyle: The initial acceptability and feasibility of a health behavior intervention for endometrial cancer survivors with obesity and their social support ne	62
Leave it in the past: Primary treatment modality for high-grade epithelial ovarian cancer does not affect secondary cytoreduction outcomes (173)	60
Neoadjuvant chemotherapy with interval debulking surgery versus chemotherapy alone for advanced epithelial ovarian cancer	59
Outcomes of splenectomy during primary cytoreductive surgery in ovarian cancer	59
Perioperative outcomes in obese women with uterine cancer	57
Recurrent ovarian cancer: maintenance treatment with PARP inhibitors in clinical practice	56
Short-term hormone replacement therapy in BRCA mutation carriers and risk of breast cancer: A nationwide study in Korea (1155)	55
Prognostic factors of survival in women with recurrent platinum-resistant epithelial ovarian cancer (1171)	54
Predictors of long-term response in prospective phase II trial of levonorgestrel intrauterine device for atypical hyperplasia and early endometrial cancer (1247)	53
TOGETHER Care: PatienT-tailOred GynEcologic Oncology posT discHargE caRe (290)	52
Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203	52
Impact of surgeon type and rurality on treatment and survival of ovarian cancer patients	51
Hot or not: defining trophoblast PD-L1 expression and lymphohistiocytic density in gestational trophoblastic neoplasia	51
Adverse postoperative outcomes associated with perioperative blood transfusion in gynecologic oncology surgery: a National Surgical Quality Improvement Program analysis (467)	49
Clinical outcomes and cost associated with HRD biomarker guided first line maintenance therapy in advanced ovarian cancer	47
Diversifying clinical trials: Does presentation at gynecologic oncology tumor board increase equitable access to clinical trials for Black and LatinX patients? (2205)	47

Clinical impact of low-volume lymph node metastases in early- stage cervical cancer: A comprehensive meta-analysis (504)	46
Comparison of solid tumor mutations under the targeted agent and profiling utilization registry (TAPUR) study: how do gynecologic cancers compare with others?	45
Determining the optimal adjuvant therapy strategy in uterine leiomyosarcoma	45
Improving the cancer survivorship journey: Developing a survivorship care transition model for rural and underserved low risk breast and gynecologic cancer patients (511)	45
Mitigating disparity? Recurrence rates and palliative care referrals by race and ethnicity across a large urban health system (514)	44
Disparities in access to high volume surgeons within high volume hospitals for hysterectomy	43
Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer	43
Impact of increased cycles of neoadjuvant chemotherapy on interval debulking surgery outcomes (541)	43
Role of lymphadenectomy for apparent early-stage low-grade serous ovarian carcinoma (529)	43
Creation of a surgical service line to treat patients with recurrent gynecologic cancer with curative intent: Complex oncologic multidisciplinary pelvic surgery (COMPS) (559)	41
Pattern of recurrence and survival: Comparative analysis of robotic radical hysterectomy with uterine manipulator versus without uterine manipulator and or vaginal cerclage in treatment of stage IB ce	41
Multi-omic and clinical data analysis of pre-menopausal women under 45 years of age diagnosed with endometrial cancer and enrolled in the ASAP trial (2154)	41
The impact of bowel preparation on surgical site infection rates in gynecologic oncology surgery, post-hoc analysis from a randomized controlled trial (550)	41
Food deserts, endometrial cancer survivors, and healthy food access: Is it equitable in rural America? – A geospatial analysis (2127)	40
Assessing somatic mutations in matched biospecimens from patients with serous ovarian cancer	40
Endometrial stripe thickness at the time of diagnosis of uterine papillary serous carcinoma in black patients (2137)	40